FAQ on Quantum BioPharma Ltd.'s Submission of MS Drug Candidate to UK ILAP Program
Summary
Quantum BioPharma Ltd. has submitted its multiple sclerosis drug candidate, Lucid-21-302, to the UK's ILAP program to accelerate its development and approval, marking a significant step in its global strategy to enhance patient access to innovative treatments.
What is Quantum BioPharma Ltd.’s recent announcement about?
Quantum BioPharma Ltd. announced that its subsidiary, Huge Biopharma Australia Pty Ltd., has submitted its patented multiple sclerosis drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) Passport program to accelerate its development and approval.
Why is the submission to the UK’s ILAP program significant?
The submission to the UK’s ILAP program is significant because it aims to accelerate access to groundbreaking treatments by streamlining the drug development and approval process, which is part of Quantum BioPharma’s global strategy to speed clinical advancement and patient access.
What is Lucid-MS?
Lucid-MS is a first-in-class therapy developed by Quantum BioPharma Ltd. that targets demyelination in multiple sclerosis, shown to prevent and reverse myelin degradation in preclinical models.
How does Quantum BioPharma Ltd. plan to benefit from the ILAP program?
Quantum BioPharma Ltd. plans to benefit from the ILAP program by leveraging strategic regulatory pathways to speed up the clinical advancement and patient access of Lucid-MS, aligning with its global strategy.
Where can I find more information about Quantum BioPharma Ltd.?
More information about Quantum BioPharma Ltd. is available in the company’s newsroom at https://ibn.fm/QNTM and through its subsidiary’s website at https://tinygems.com/tiny-gems/quantum-biopharma-ltd/.
What other projects or subsidiaries is Quantum BioPharma Ltd. involved in?
Quantum BioPharma Ltd. is involved in various projects including the development of UNBUZZD(TM) through its subsidiary Celly Nutrition Corp., and maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc.
What are the terms of Quantum BioPharma’s agreement with Celly Nutrition Corp.?
The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity, with Quantum retaining 100% rights to develop similar products for pharmaceutical and medical uses.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99205